Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03976596 · ClinicalTrials.gov registry record
Measurement of in Vivo Mitochondrial Capacity in Infants
A clinical trial, sponsored by Pennington Biomedical Research Center.
- Terminated
- Registry status
- 2
- Enrollment target
NCT03976596 is a clinical trial that was terminated before completion, run by Pennington Biomedical Research Center. The registered enrollment target is 2 participants.
The verdict
NCT03976596 was terminated before completion, sponsored by Pennington Biomedical Research Center.
- TERMINATED
- Registry status
- 2 participants
- Enrollment target
Study Summary
The overarching aim of this project is to determine the test re-test reliability of 31P-magnetic resonance spectroscopy measurements in infants. Primary endpoints include two separate measures of in vivo mitochondrial capacity (ATPmax) over a 1-10 day period to assess feasibility and reliability.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2019-05-21 |
| Est. Completion | 2019-07-02 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03976596
The ClinicalTrials.gov registry entry for NCT03976596 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pennington Biomedical Research Center, which has 258 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT03976596 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03976596 about?
NCT03976596 is a clinical study titled "Measurement of in Vivo Mitochondrial Capacity in Infants". The overarching aim of this project is to determine the test re-test reliability of 31P-magnetic resonance spectroscopy measurements in infants. Primary endpoints include two separate measures of in vivo mitochondrial capacity (ATPmax) over a 1-10 day period to assess feasibility and reliability.
What is the current status of trial NCT03976596?
This trial is currently terminated. The enrollment target is 2 participants. The study started on 2019-05-21. Estimated completion is 2019-07-02.
Who is sponsoring clinical trial NCT03976596?
This trial is sponsored by Pennington Biomedical Research Center, which has 258 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.